Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Liffers, Sven T ^a   Tilkorn, Daniel J ^b   Stricker, Ingo ^a   Junge, Christoph G ^a   Al Benna, Sammy ^b   Vogt, Markus ^a   Verdoodt, Berlinda ^a   Steinau, Hans U ^b   Tannapfel, Andrea ^a   Tischoff, Iris ^a   Mirmohammadsadegh, Alireza ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Apoptosis; Chemotherapy; Doxorubicin; Malignant soft tissue tumors; Salinomycin

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SALINOMYCIN;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROSARCOMA; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; LIPOSARCOMA; MONOTHERAPY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; PYRANS; SARCOMA; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885708784     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-490     Document Type: Article

References (30)

1. Fletcher CDM SM, Rydholm A, Coindre JM, Singer S. Soft tissue tumours: Epidemiology, clinical features, histopathological typing and grading. World Health Organisation classification of tumours pathology and genetics of tumours of soft tissue and bone 2002, Lyon: World Health Organization, Christopher DM, Fletcher K, Unni K, Mertens F.
2. Karakousis CP, Perez RP. Soft tissue sarcomas in adults. CA Cancer J Clin 1994, 44:200-210. 10.3322/canjclin.44.4.200, 8019927.
3. Kasper B, Gil T, D'Hondt V, Gebhart M, Awada A. Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 2007, 62:9-15. 10.1016/j.critrevonc.2006.11.008, 17141519.
4. Pisters P. Staging and prognosis. American cancer society atlas of clinical oncology: soft tissue sarcomas 2002, 80-88. Hamilton, Ontario: BC Decker, Inc, Pollock RE.
5. Nitiss JL. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr Opin Investig Drugs 2002, 3:1512-1516.
6. Bidwell GL, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 2006, 71:248-256. 10.1016/j.bcp.2005.10.041, 16316634.
7. Hsiao CJ, Li TK, Chan YL, Hsin LW, Liao CH, Lee CH, Lyu PC, Guh JH. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Biochem Pharmacol 2008, 75:847-856. 10.1016/j.bcp.2007.10.012, 18035333.
8. Gluck S. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 2005, 10:780-791. 10.1634/theoncologist.10-10-780, 16314288.
9. Gluck S. New advances in the management of metastatic breast cancer. J Natl Compr Canc Netw 2005, 3(Suppl 1):S12-S16.
10. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, Green JA. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of cochrane collaboration. Ann Oncol 2007, 18:409-420.
11. Thomadaki H, Scorilas A. Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect Tissue Res 2008, 49:261-264. 10.1080/03008200802147829, 18661356.
12. Chakraborty P, Sk UH, Bhattacharya S. Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate. Cancer Chemother Pharmacol 2009, 64:971-980. 10.1007/s00280-009-0950-8, 19221751.
13. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659. 10.1016/j.cell.2009.06.034, 19682730.
14. Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun 2009, 390:743-749. 10.1016/j.bbrc.2009.10.042, 19835841.
15. Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol 2011, 162:773-784. 10.1111/j.1476-5381.2010.01089.x, 3041264, 20973777.
16. Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, Yoon S. Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs 2011, 30:1311-1318.
17. Breitinger H-G. Drug synergy - mechanisms and methods of analysis. Toxicity and Drug Testing 2012, Acree W, http://www.intechopen.com/books/toxicity-and-drug-testing/drug-synergy-mechanisms-and-methods-of-analysis.
18. Bednarski BK, Baldwin AS, Kim HJ. Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS One 2009, 4:e6992. 10.1371/journal.pone.0006992, 2734988, 19746155.
19. Hellin AC, Calmant P, Gielen J, Bours V, Merville MP. Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 1998, 16:1187-1195. 10.1038/sj.onc.1201638, 9528861.
20. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N. Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor kappaB activity. J Biol Chem 1999, 274:35240-35246. 10.1074/jbc.274.49.35240, 10575010.
21. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003, 3:895-902. 10.1038/nrc1232, 14737120.
22. Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 2010, 394:1098-1104. 10.1016/j.bbrc.2010.03.138, 20350531.
23. Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH. Salinomycin selectively targets 'CD133 +' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol 2011, 18:1797-1804. 10.1245/s10434-011-1561-2, 21267784.
24. Verdoodt B, Vogt M, Schmitz I, Liffers ST, Tannapfel A, Mirmohammadsadegh A. Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS One 2012, 7:e44132. 10.1371/journal.pone.0044132, 3446972, 23028492.
25. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000, 404:892-897. 10.1038/35009130, 10786798.
26. Javelaud D, Wietzerbin J, Delattre O, Besancon F. Induction of p21Waf1/Cip1 by TNFalpha requires NF-kappaB activity and antagonizes apoptosis in ewing tumor cells. Oncogene 2000, 19:61-68. 10.1038/sj.onc.1203246, 10644980.
27. Zhang Y, Wu Y, Wu D, Tashiro S, Onodera S, Ikejima T. NF-kappab facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway. Arch Biochem Biophys 2009, 489:25-33. 10.1016/j.abb.2009.07.017, 19646415.
28. Zhang LH, Youn HD, Liu JO. Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NFkappa B-dependent activation of p53. J Biol Chem 2001, 276:43534-43540. 10.1074/jbc.M104257200, 11557753.
29. Wang P, Qiu W, Dudgeon C, Liu H, Huang C, Zambetti GP, Yu J, Zhang L. PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ 2009, 16:1192-1202. 10.1038/cdd.2009.51, 2872087, 19444283.
30. Liu D, Ou L, Clemenson GD, Chao C, Lutske ME, Zambetti GP, Gage FH, Xu Y. Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol 2010, 12:993-998. 10.1038/ncb2100, 3025300, 20818388.